Speeding Up SARS Research

CombiMatrix develops a series of microarrays for severe acute respiratory syndrome

Courtesy of CombiMatrix

Following closely on the heels of the publication of the SARS (severe acute respiratory syndrome) coronavirus genome, Mukilteo, Wash.-based CombiMatrix recently announced the release of the first SARS microarray. The array will be made available at no cost to a limited number of government and academic research centers, says Ali Arjomand, senior scientist at CombiMatrix. The company plans to launch three types of chips: for detection and screening; for genome-wide detection of viral mutations; and for the study of viral and/or host gene expression.

The array for mutation typing, which compares the hybridization pattern of a previously sequenced viral genome with a sample from a patient, is designed to identify new viral variants and the regions of the genomes in which the two versions differ. But Arjomand says that, as a drug...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?